Skip to main content
Himisha Beltran, MD, Oncology, New York, NY

HimishaBeltranMD

Oncology • New York, NY

Associate Professor of Medicine, Dana Farber Cancer Institute, Harvard Medical School

Request Appointment

Overview of Dr. Beltran

Dr. Himisha Beltran is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, Dana-Farber Cancer Institute, and Brigham and Women's Hospital. She received her medical degree from New York Medical College and has been in practice 18 years. She is one of 453 doctors at Dana-Farber Cancer Institute and one of 376 doctors at Brigham and Women's Hospital who specialize in Oncology. She has more than 100 publications and over 500 citings.

Education & Training

  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2008 - 2011
  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemResidency, Internal Medicine, 2004 - 2007
  • New York Medical College
    New York Medical CollegeClass of 2004

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2019 - 2025
  • NH State Medical License
    NH State Medical License 2024 - 2024
  • NY State Medical License
    NY State Medical License 2008 - 2019
  • PA State Medical License
    PA State Medical License 2007 - 2008
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Activity of Platinum-Based Chemotherapy in Patients with Advanced Prostate Cancer with and Without DNA Repair Gene Aberrations  
    Himisha Beltran, Che-Kai Tsao, Tomasz M Beer, JAMA Network Open

Press Mentions

  • The Challenge of Finding New Tools to Fight Prostate Cancer
    The Challenge of Finding New Tools to Fight Prostate CancerSeptember 9th, 2021
  • BET Inhibitors Show Promise in Overcoming Lineage Plasticity, a Newly Recognized Form of Resistance to Prostate Cancer Drugs
    BET Inhibitors Show Promise in Overcoming Lineage Plasticity, a Newly Recognized Form of Resistance to Prostate Cancer DrugsJune 18th, 2021
  • Dana-Farber Cancer Institute, a Pioneer in Cancer Care and Research, Joins Caris' Precision Oncology Alliance
    Dana-Farber Cancer Institute, a Pioneer in Cancer Care and Research, Joins Caris' Precision Oncology AllianceFebruary 16th, 2021
  • Join now to see all

Professional Memberships

Dr. Himisha Beltran, Dr. Himisha Beltran, MD, Dr. H Beltran